MEDIFAST INC Earnings Per Share Disclosure
| 2025 | 2024 | 2023 | |||||||||||||||
| Numerator: | |||||||||||||||||
Net income (loss) | $ | (18,672) | $ | 2,091 | $ | 99,415 | |||||||||||
| Denominator: | |||||||||||||||||
| Weighted average shares of common stock outstanding | 10,981 | 10,930 | 10,884 | ||||||||||||||
| Effect of dilutive common stock equivalents | — | 33 | 37 | ||||||||||||||
| Weighted average shares of common stock outstanding | 10,981 | 10,963 | 10,921 | ||||||||||||||
Earnings (loss) per share - basic | $ | (1.70) | $ | 0.19 | $ | 9.13 | |||||||||||
Earnings (loss) per share - diluted | $ | (1.70) | $ | 0.19 | $ | 9.10 | |||||||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 17, 2026 | Showing above |
| 2024 | Feb 18, 2025 | |
| 2023 | Feb 20, 2024 | |
| 2022 | Feb 21, 2023 | |
| 2021 | Feb 23, 2022 | |
| 2020 | Feb 26, 2021 | |
| 2019 | Mar 2, 2020 | |
| 2018 | Mar 1, 2019 | |
| 2017 | Mar 16, 2018 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.